---
schema_version: "secwatch.filing_event.v1"
accession: "0000914121-22-004052"
form_type: "8-K"
ticker: "ANGO"
cik: "0001275187"
company_name: "ANGIODYNAMICS INC"
filed_at: "2022-07-12T23:59:59+00:00"
generated_at: "2026-06-24T16:26:46.254965+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AngioDynamics Q4 sales $87M (+13% YoY), GAAP EPS -$0.16; FY23 rev guide $342-348M

## Summary
- Q4 net sales $87.0M (+13.2% YoY); Med Tech sales up 40% to $22.6M.
- GAAP loss per share $0.16; adjusted EPS $0.01; full-year GAAP loss $0.68.
- Full-year net sales $316.2M (+8.7% YoY); gross margin declined 150 bps to 52.4%.
- FY2023 guidance: net sales $342-348M, gross margin 52.5-54.5%, adjusted EPS $0.01-$0.06.
- Cash $28.8M at May 31; $25M drawn on revolver; operating cash flow $8.6M in Q4.

## SEC filing metadata
- accession: 0000914121-22-004052
- form_type: 8-K
- ticker: ANGO
- cik: 0001275187
- company_name: ANGIODYNAMICS INC
- filed_at: 2022-07-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1275187/000091412122004052/0000914121-22-004052-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1275187/000091412122004052/an58016818-8ki.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914121-22-004052
- JSON: https://secwatch.observer/filing/0000914121-22-004052.json
- Plain text: https://secwatch.observer/filing/0000914121-22-004052.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.